Most people who recovered from COVID-19 had normal thyroid function six months later, but some developed mild thyroid hormone deficiency and higher levels of thyroid antibodies, suggesting possible long-term thyroid changes. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether post-COVID subclinical hypothyroidism and anti-TPO elevation occur more frequently than in other severe infections or the general population.
A systematic review and meta-analysis of all prospective cohort studies measuring TFTs and anti-TPO at 6 months in adults recovering from confirmed COVID-19, compared to matched controls with non-COVID respiratory illness or healthy individuals, including at least 15,000 participants.
An RCT could test whether early thyroid hormone replacement in post-COVID patients with elevated anti-TPO prevents progression to overt hypothyroidism.
A double-blind RCT of 300 adults with post-COVID subclinical hypothyroidism and anti-TPO >100 IU/mL, randomized to levothyroxine 25 mcg/day vs. placebo for 12 months, with primary outcome being progression to overt hypothyroidism (TSH >10 mIU/L).
A prospective cohort could confirm the incidence and persistence of subclinical hypothyroidism and anti-TPO elevation in COVID-19 survivors over time.
A multicenter prospective cohort of 1,000 adults discharged after hospitalization for COVID-19, measuring TSH, fT4, and anti-TPO at discharge, 3 months, and 6 months, with baseline measurements available, adjusting for age, sex, and pre-existing autoimmunity.
A case-control study could compare anti-TPO levels in post-COVID patients with subclinical hypothyroidism to those without, identifying potential risk factors.
A matched case-control study of 200 post-COVID patients with subclinical hypothyroidism (TSH >4.5 mIU/L) and 200 without, matched for age, sex, and severity of acute illness, measuring anti-TPO, anti-Tg, and pre-infection thyroid history.
A cross-sectional study could estimate the prevalence of subclinical hypothyroidism and elevated anti-TPO in a single group of recovered patients.
A single-timepoint survey of 500 adults 6 months after hospital discharge for COVID-19, measuring TSH and anti-TPO to estimate prevalence and crude association with acute illness severity.